Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma (CELEBRIDO)

NCT03896113 PHASE2 UNKNOWN

Indoleamine 2,3 dioxygenase 1 (IDO 1) is the major enzyme catabolising the Tryptophan outside the liver. It has been shown that its plays a important role in generating a immunosuppressive micro-environment in tumors. IDO expression has been shown by Hennequart et al. to be driven by Cyclooxygenase-2 (COX-2) expression. The investigator's team also shown that anti-COX2, celecoxib, can in a xenograft models of ovarian cancer decrease IDO1 expression and result in an infiltration of the tumor by T cells. The investigator proposed then to conduct a proof of concept study to evaluate the effect of pre-operative short administration of Celecoxib on IDO expression and Immune cells tumors infiltration, in patients with endometrial cancer. Indeed, this tumor type is well known to express frequently a high level of IDO.

Details

Lead sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase	PHASE2
Status	UNKNOWN
Enrolment	48
Start date	Wed Nov 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jun 30 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Endometrium Cancer

Interventions

• Celecoxib 200mg capsule

Countries

Belgium